



10 August 2021

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

cyclomedica
technegas
ultralute

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

CYCLOPHARM APPOINTS NON-EXECUTIVE DIRECTOR

Cyclopharm Limited (CYC) today announced the appointment of Ms Dianne Angus to the Board of Directors. Ms Angus joined the Board as a Non-Executive Director with the appointment effective from 10 August 2021.

Ms Angus is also a Non-Executive Director of ASX Listed Companies Imagion Biosystems Limited and Neuren Pharmaceuticals Limited. She brings deep executive experience in the Biotechnology industry including with Prana Biotechnology Limited (now Alterity Therapeutics) and Florigene Limited. Dianne also has wide expertise in corporate strategy, innovative product development, governance and compliance in our sector.

Dianne holds a Master of Biotechnology, Bachelor of Science (Hons) and a Graduate Diploma of Intellectual Property Law. She is a registered patent attorney and a member of the Institute of Company Directors.

Ms Angus said "I am delighted to join the Board of Cyclopharm Limited at such an exciting time as the company moves through the final stages of obtaining USFDA approval to its proprietary product, Technegas, and then to further develop its markets beyond pulmonary embolism."

Mr David Heaney, Chairman of Cyclopharm Limited said " We are extremely pleased to welcome Dianne as a fellow Director. Dianne's extensive experience, both as an executive and a Director in the Bio-tech industry will enable her to provide valuable insight as the Company expands its horizons."

- ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®

The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnace for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.